BioGaia AB (LTS:0GTN) Cash And Cash Equivalents : kr1,591 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is BioGaia AB Cash And Cash Equivalents?

BioGaia AB's quarterly cash and cash equivalents increased from Sep. 2023 (kr1,452.53 Mil) to Dec. 2023 (kr1,544.19 Mil) and increased from Dec. 2023 (kr1,544.19 Mil) to Mar. 2024 (kr1,591.39 Mil).

BioGaia AB's annual cash and cash equivalents increased from Dec. 2021 (kr1,484.68 Mil) to Dec. 2022 (kr1,488.37 Mil) and increased from Dec. 2022 (kr1,488.37 Mil) to Dec. 2023 (kr1,544.19 Mil).

BioGaia AB Cash And Cash Equivalents Historical Data

The historical data trend for BioGaia AB's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGaia AB Cash And Cash Equivalents Chart

BioGaia AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

213.83

1,467.88

1,484.68

1,488.37

1,544.19

BioGaia AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															1,580.82	1,369.57	1,452.53	1,544.19	1,591.39

BioGaia AB Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

BioGaia AB (LTS:0GTN) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

BioGaia AB Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of BioGaia AB's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

BioGaia AB (LTS:0GTN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioGaia AB (LTS:0GTN) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

BIOGY:USA BGLAF:USA BIOG B:Sweden BGLA:Germany

Address

Kungsbroplan 3A, Stockholm, SWE, SE-112 27

Website

https://www.biogaia.se

BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.

BioGaia AB (LTS:0GTN) Headlines

No Headlines